History

TB-500 is a synthetic heptapeptide corresponding to the actin-binding active region (residues 17-23, sequence LKKTETQ) of thymosin beta-4, a naturally occurring 43-amino-acid protein found throughout mammalian tissues. The fragment was made to reproduce thymosin beta-4's cell-migration and repair activity in a smaller, more stable molecule. The two should not be confused: full-length thymosin beta-4 has been studied clinically, whereas TB-500 — the fragment — has no approved human use and appears mainly in research, gray-market, and animal-doping settings.

TB-500 is a lab-made peptide sold widely as a “healing” and recovery compound. It is worth separating clearly from the natural protein it is derived from, because much of the optimistic marketing borrows credibility from research that did not actually use TB-500.

What it is

Thymosin beta-4 (Tβ4) is a naturally occurring protein of about 43-44 amino acids that helps regulate actin, a building block of the cell skeleton. It plays a role in cell movement, wound healing, and inflammation. TB-500 is not full-length Tβ4. It is a short synthetic fragment built around the protein’s actin-binding region, sold almost entirely through research-chemical channels rather than pharmacies.

The claims

Vendors and forums promote TB-500 for faster healing of muscle, tendon, and ligament injuries, reduced inflammation, improved flexibility, hair growth, and general recovery. These claims are usually attached to subcutaneous or intramuscular injection.

What the evidence actually shows

This is where the gap is largest. The healing claims rest mainly on animal and cell studies of thymosin beta-4, which do show effects on wound repair, corneal healing, and tissue regeneration in rodents and laboratory models.

Human trials do exist, but they tested the full-length Tβ4 molecule, not the TB-500 fragment, and mostly for indications unrelated to athletic recovery. RegeneRx developed Tβ4-based products including an ophthalmic formulation (RGN-259) for dry eye and neurotrophic keratopathy and an injectable (RGN-352) aimed at cardiac and other tissue injury; the eye-drop program has reported reaching late-stage (phase 3) trials for neurotrophic keratopathy, while results across the broader program have been mixed and none has reached FDA approval. A first-in-human phase I study in China tested recombinant Tβ4 (44 amino acids) given intravenously in healthy volunteers and found it well tolerated, but it was a safety and dose-finding study, not proof of benefit.

Critically, no completed phase 2 or phase 3 randomized controlled trial has tested injectable TB-500 (or Tβ4) for tendon, ligament, or muscle injury in people. So the exact thing most buyers want it for has essentially no direct human efficacy evidence.

Legal and regulatory status

TB-500 is not approved by the FDA for any human use. Its compounding status is unsettled and in flux. The FDA had placed thymosin beta-4 in Category 2 of its interim list of bulk drug substances for 503A pharmacy compounding — the category for substances that may present significant safety risks, which effectively blocked compounding — citing concerns such as immunogenicity, impurities, and limited human safety data. In April 2026, however, the FDA removed thymosin beta-4 (along with several other peptides) from Category 2 after the nominations were withdrawn, and scheduled it for review by the Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026. Removal from Category 2 does not mean it is approved or freely compoundable: thymosin beta-4 has never been on Category 1 (the list of substances permitted for compounding), so its status remains unresolved pending that review and any later rulemaking. Products sold online are labeled “research use only” and are not quality-controlled as medicines.

In sport, TB-500 is banned. WADA and USADA prohibit thymosin beta-4 and its derivatives at all times (in and out of competition) under Section S2 (peptide hormones, growth factors, and related substances); it has been prohibited since the 2012 Prohibited List took effect, and athletes have been sanctioned for it.

Safety

Honest answer: the safety of the TB-500 fragment in humans is largely unstudied. Full-length Tβ4 was generally well tolerated in small early trials, but that does not transfer automatically to a different molecule made by unregulated vendors. Independent testing of research-chemical peptides repeatedly finds mismatched content, impurities, and contamination, which adds risk beyond the peptide itself. A theoretical concern often raised is that a compound promoting tissue growth and blood-vessel formation could also affect tumor growth; this has not been resolved in humans. Nothing here is medical advice.

Bottom line

TB-500’s reputation is built on animal data for a related-but-different molecule, plus a handful of human trials of full-length Tβ4 that did not test the fragment for the uses it is sold for. It is unapproved, not currently permitted for compounding, banned in sport, and sold through unregulated channels. Treat strong healing claims as unproven.

Evidence grade: Animal only.

Sources

A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers (PMC)
Progress on the Function and Application of Thymosin β4 (review, Frontiers in Endocrinology)
FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know (FDA Law Blog, April 2026)
USADA — 2018 Prohibited List: Summary of Major Changes
TB-500 — Status, Risks, and Bans in Sport and Military (BSCG)
FDA, Bulk Drug Substances Used in Compounding Under Section 503A (interim list / Category 2 designations)
RegeneRx Biopharmaceuticals — Tβ4-based clinical programs (RGN-259 ophthalmic; RGN-352 injectable)